Lilly announces top-line phase 3 results for oral JAK inhibitor baricitinib
Eli Lilly and Incyte announced that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial in the BREEZE-AD program to be completed in 2019. BREEZE-AD7, an investigational study evaluating efficacy and safety of baricitinib to treat moderate to severe AD. August 23, 2019